A meta-analysis of randomized double-blind clinical trials in CMT1A to assess the change from baseline in CMTNS and ONLS scales after one year of treatment

CMT1A is the most common inherited peripheral neuropathy. There is currently no approved treatment. We performed a meta-analysis including four randomized, double-blind, Placebo-controlled clinical trials to assess the disease progression after one year under Placebo, Ascorbic Acid (AA) or PXT3003,...

Descripción completa

Detalles Bibliográficos
Autores principales: Mandel, Jonas, Bertrand, Viviane, Lehert, Philippe, Attarian, Shahram, Magy, Laurent, Micallef, Joëlle, Chumakov, Ilya, Scart-Grès, Catherine, Guedj, Mickael, Cohen, Daniel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Letter to the Editor
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4482281/
https://www.ncbi.nlm.nih.gov/pubmed/26070802
http://dx.doi.org/10.1186/s13023-015-0293-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4482281/
https://www.ncbi.nlm.nih.gov/pubmed/26070802
http://dx.doi.org/10.1186/s13023-015-0293-y

Ejemplares similares